XML 31 R71.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding (USD $)
12 Months Ended
Dec. 31, 2014
SARS 1  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
Range of exercise price $ 4.90us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
/ us-gaap_AwardTypeAxis
= sgc_SARS1Member
SARS (in Shares) 33,184us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
/ us-gaap_AwardTypeAxis
= sgc_SARS1Member
Weighted average remaining contractual life (years) 29 days
Weighted average exercise price $ 4.90sgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionOutstandingWeightedAverageGrantDateFairValue
/ us-gaap_AwardTypeAxis
= sgc_SARS1Member
SARS 2 | Minimum [Member]  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
Range of exercise price $ 5.62us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
/ us-gaap_AwardTypeAxis
= sgc_SARS2Member
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
SARS 2 | Maximum [Member]  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
Range of exercise price $ 7.36us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
/ us-gaap_AwardTypeAxis
= sgc_SARS2Member
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
SARS 2  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
SARS (in Shares) 488,840us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
/ us-gaap_AwardTypeAxis
= sgc_SARS2Member
Weighted average remaining contractual life (years) 2 years 178 days
Weighted average exercise price $ 6.26sgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionOutstandingWeightedAverageGrantDateFairValue
/ us-gaap_AwardTypeAxis
= sgc_SARS2Member
SARS 3 | Minimum [Member]  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
Range of exercise price $ 4.90us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
/ us-gaap_AwardTypeAxis
= sgc_SARS3Member
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
SARS 3 | Maximum [Member]  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
Range of exercise price $ 7.36us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
/ us-gaap_AwardTypeAxis
= sgc_SARS3Member
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
SARS 3  
Note 12 - Share-based Compensation (Details) - Summary of Information About Stock Appreciation Rights Outstanding [Line Items]  
SARS (in Shares) 522,024us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
/ us-gaap_AwardTypeAxis
= sgc_SARS3Member
Weighted average remaining contractual life (years) 2 years 124 days
Weighted average exercise price $ 6.17sgc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionOutstandingWeightedAverageGrantDateFairValue
/ us-gaap_AwardTypeAxis
= sgc_SARS3Member